4D Molecular Therapeutics, Inc. (FDMT)

Market Cap	513.65M +70.4%
Revenue (ttm)	120,000 +605.9%
Net Income	-209.18M
EPS	-3.74
Shares Out	51.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	654,728
Open	9.74
Previous Close	9.68
Day's Range	9.72 - 10.48
52-Week Range	2.24 - 12.34
Beta	3.01
Analysts	Strong Buy
Price Target	34.13 (+238.93%)
Earnings Date	Feb 27, 2026

About FDMT

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 227
• Stock Exchange: NASDAQ
• Ticker Symbol: FDMT

Financial Performance

In 2024, 4D Molecular Therapeutics's revenue was $37,000, a decrease of -99.82% compared to the previous year's $20.72 million. Losses were -$160.87 million, 59.5% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for FDMT stock is "Strong Buy." The 12-month stock price target is $34.13, which is an increase of 238.93% from the latest price.

Price Target

$34.13

(238.93% upside)

Analyst Consensus: Strong Buy